Diabeteksen munuaistauti, näytönastekatsausten kirjallisuusviitteet

Kirjallisuutta

1. Adler AI, Stevens RJ, Manley SE ym. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32 «PMID: 12472787»PubMed
2. Agrawal L, Azad N, Bahn GD ym. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia 2018;61:295-299 «PMID: 29101421»PubMed
3. Baggio B, Budakovic A, Dalla Vestra M ym. Effects of cigarette smoking on glomerular structure and function in type 2 diabetic patients. J Am Soc Nephrol 2002;13:2730-6 «PMID: 12397043»PubMed
4. Baigent C, Landray MJ, Reith C ym. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92 «PMID: 21663949»PubMed
5. Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999;22:307-13 «PMID: 10333950»PubMed
6. Bakris GL, Williams M, Dworkin L ym. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61 «PMID: 10977801»PubMed
7. Billeter AT, Scheurlen KM, Probst P ym. Meta-analysis of metabolic surgery versus medical treatment for microvascular complications in patients with type 2 diabetes mellitus. Br J Surg 2018;105:168-181 «PMID: 29405276»PubMed
8. Brenner BM, Cooper ME, de Zeeuw D ym. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9 «PMID: 11565518»PubMed
9. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 2005;:S87-93 «PMID: 16336584»PubMed
10. Chase HP, Garg SK, Marshall G ym. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991;265:614-7 «PMID: 1987411»PubMed
11. Chen Y, Zhi Y, Li C ym. HDL cholesterol and risk of diabetic nephropathy in patient with type 1 diabetes: A meta-analysis of cohort studies. Diabetes Res Clin Pract 2016;122:84-91 «PMID: 27816683»PubMed
12. Chronic Kidney Disease Prognosis Consortium., Matsushita K, van der Velde M ym. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81 «PMID: 20483451»PubMed
13. Chuahirun T, Simoni J, Hudson C ym. Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Med Sci 2004;327:57-67 «PMID: 14770020»PubMed
14. de Boer IH, Gao X, Cleary PA ym. Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clin J Am Soc Nephrol 2016;11:1969-1977 «PMID: 27797889»PubMed
15. Diabetes Control and Complications Trial Research Group., Nathan DM, Genuth S ym. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86 «PMID: 8366922»PubMed
16. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413-8 «PMID: 9224218»PubMed
17. Dwyer JP, Parving HH, Hunsicker LG ym. Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study. Cardiorenal Med 2012;2:1-10 «PMID: 22493597»PubMed
18. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9 «PMID: 10675071»PubMed
19. Feodoroff M, Harjutsalo V, Forsblom C ym. Smoking and progression of diabetic nephropathy in patients with type 1 diabetes. Acta Diabetol 2016;53:525-33 «PMID: 26668013»PubMed
20. Gaede P, Vedel P, Larsen N ym. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93 «PMID: 12556541»PubMed
21. Gall MA, Borch-Johnsen K, Hougaard P ym. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995;44:1303-9 «PMID: 7589828»PubMed
22. Gansevoort RT, Verhave JC, Hillege HL ym. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl 2005;:S28-35 «PMID: 15752236»PubMed
23. Gerstein HC, Mann JF, Yi Q ym. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6 «PMID: 11466120»PubMed
24. Gozzoli V, Palmer AJ, Brandt A ym. [Increased clinical and economic advantages using PROSIT (proteinuria screening and intervention) in type 2 diabetic patients]. Dtsch Med Wochenschr 2000;125:1154-9 «PMID: 11075242»PubMed
25. Groop PH, Thomas MC, Moran JL ym. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-8 «PMID: 19401416»PubMed
26. Holman RR, Paul SK, Bethel MA ym. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89 «PMID: 18784090»PubMed
27. Houlihan CA, Tsalamandris C, Akdeniz A ym. Albumin to creatinine ratio: a screening test with limitations. Am J Kidney Dis 2002;39:1183-9 «PMID: 12046029»PubMed
28. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53 «PMID: 9742976»PubMed
29. Jansson FJ, Forsblom C, Harjutsalo V ym. Regression of albuminuria and its association with incident cardiovascular outcomes and mortality in type 1 diabetes: the FinnDiane Study. Diabetologia 2018;61:1203-1211 «PMID: 29423580»PubMed
30. Koye DN, Magliano DJ, Reid CM ym. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis 2018;72:653-661 «PMID: 29784612»PubMed
31. Kramer HJ, Nguyen QD, Curhan G ym. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273-7 «PMID: 12824208»PubMed
32. Lewis EJ, Hunsicker LG, Bain RP ym. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62 «PMID: 8413456»PubMed
33. Lewis EJ, Hunsicker LG, Clarke WR ym. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60 «PMID: 11565517»PubMed
34. MacLeod JM, Lutale J, Marshall SM. Albumin excretion and vascular deaths in NIDDM. Diabetologia 1995;38:610-6 «PMID: 7489846»PubMed
35. Mann JFE, Ørsted DD, Brown-Frandsen K ym. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017;377:839-848 «PMID: 28854085»PubMed
36. Marso SP, Bain SC, Consoli A ym. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834-1844 «PMID: 27633186»PubMed
37. Metsärinne K, Bröijersen A, Kantola I ym. High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care. Prim Care Diabetes 2015;9:31-8 «PMID: 25066820»PubMed
38. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-60 «PMID: 6690964»PubMed
39. Nathan DM, Cleary PA, Backlund JY ym. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53 «PMID: 16371630»PubMed
40. Newman DJ, Mattock MB, Dawnay AB ym. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005;9:iii-vi, xiii-163 «PMID: 16095545»PubMed
41. O'Brien R, Johnson E, Haneuse S ym. Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study. Ann Intern Med 2018;169:300-310 «PMID: 30083761»PubMed
42. Oellgaard J, Gæde P, Rossing P ym. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia 2018;61:1724-1733 «PMID: 29850922»PubMed
43. Packham DK, Alves TP, Dwyer JP ym. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis 2012;59:75-83 «PMID: 22051245»PubMed
44. Palmer SC, Navaneethan SD, Craig JC ym. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014;:CD007784 «PMID: 24880031»PubMed
45. Parving HH, Lehnert H, Bröchner-Mortensen J ym. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8 «PMID: 11565519»PubMed
46. Penno G, Solini A, Bonora E ym. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens 2011;29:1802-9 «PMID: 21738053»PubMed
47. Penno G, Solini A, Bonora E ym. Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Acta Diabetol 2018;55:603-612 «PMID: 29574497»PubMed
48. Penno G, Solini A, Orsi E ym. Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study. Diabetologia 2018;61:2277-2289 «PMID: 30032426»PubMed
49. Perkins BA, Ficociello LH, Roshan B ym. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010;77:57-64 «PMID: 19847154»PubMed
50. Perkovic V, de Zeeuw D, Mahaffey KW ym. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 2018;6:691-704 «PMID: 29937267»PubMed
51. Persson F, Lindhardt M, Rossing P ym. Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review. J Renin Angiotensin Aldosterone Syst 2016;17: «PMID: 27488274»PubMed
52. Pfeffer MA, Claggett B, Diaz R ym. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015;373:2247-57 «PMID: 26630143»PubMed
53. Rahman M, Baimbridge C, Davis BR ym. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis 2008;52:412-24 «PMID: 18676075»PubMed
54. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group., Lachin JM, Genuth S ym. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9 «PMID: 10666428»PubMed
55. Retnakaran R, Cull CA, Thorne KI ym. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006;55:1832-9 «PMID: 16731850»PubMed
56. Rodríguez-Gutiérrez R, Montori VM. Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence. Circ Cardiovasc Qual Outcomes 2016;9(5):504-12
57. Ruggenenti P, Fassi A, Ilieva AP ym. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51 «PMID: 15516697»PubMed
58. Ruggenenti P, Porrini E, Motterlini N ym. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol 2012;23:1717-24 «PMID: 22935482»PubMed
59. Ruospo M, Saglimbene VM, Palmer SC ym. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev 2017;6:CD010137 «PMID: 28594069»PubMed
60. Sawicki PT, Didjurgeit U, Mühlhauser I ym. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994;17:126-31 «PMID: 8137682»PubMed
61. Targher G, Zoppini G, Chonchol M ym. Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. Nutr Metab Cardiovasc Dis 2011;21:294-301 «PMID: 20096544»PubMed
62. Diabetes Control and Complications Trial Research Group., Nathan DM, Genuth S ym. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86 «PMID: 8366922»PubMed
63. Thomas MC, Macisaac RJ, Jerums G ym. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 2009;32:1497-502 «PMID: 19470839»PubMed
64. Thorn LM, Gordin D, Harjutsalo V ym. The Presence and Consequence of Nonalbuminuric Chronic Kidney Disease in Patients With Type 1 Diabetes. Diabetes Care 2015;38:2128-33 «PMID: 26310691»PubMed
65. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13 «PMID: 9732337»PubMed
66. Wanner C, Inzucchi SE, Lachin JM ym. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016;375:323-34 «PMID: 27299675»PubMed
67. Wiviott SD, Raz I, Bonaca MP ym. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019;380:347-357 «PMID: 30415602»PubMed
68. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-67
69. Wu HY, Peng YS, Chiang CK ym. Diagnostic performance of random urine samples using albumin concentration vs ratio of albumin to creatinine for microalbuminuria screening in patients with diabetes mellitus: a systematic review and meta-analysis. JAMA Intern Med 2014;174:1108-15 «PMID: 24798807»PubMed
70. Zelniker TA, Wiviott SD, Raz I ym. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31-39 «PMID: 30424892»PubMed
71. Zhu HG, Jiang ZS, Gong PY ym. Efficacy of low-protein diet for diabetic nephropathy: a systematic review of randomized controlled trials. Lipids Health Dis 2018;17:141 «PMID: 29914534»PubMed
72. Zoungas S, Arima H, Gerstein HC ym. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017;5:431-437 «PMID: 28365411»PubMed